Te Rūnanga o Ngāti Whātua and Roche Pharmaceuticals New Zealand proudly announce the signing of an agreement to explore new avenues for disease prevention, treatment, and wellness for the descendants of Ngāti Whātua.
The “Tū Kotahi” relationship agreement, thought to be a world first between a global pharmaceuticals company and Iwi Māori tribal organisation, signifies the commitment of both organisations to inclusivity, respect, and understanding of indigenous knowledge and practices.
Dame Rangimarie Naida Glavish, and John Marsden, Co-Chairs of Te Runanga o Ngati Whatua, said the relationship signified a new chapter in healthcare innovation and cultural preservation.
“This relationship gives Te Rūnanga o Ngāti Whātua a platform to bring new ways of treatment and healthcare innovation for the descendants of Ngāti Whātua by integrating traditional Māori values and matauranga into modern healthcare solutions.”
Maori health inequity overlaps with Roche areas, particularly cancer awareness, diagnosis, treatment and therapies (liver, lung, breast), and Opthamology (eye health often linked to diabetes).
Signing for Roche Pharmaceuticals, NZ General Manager Alex Muelhaupt said putting patients first means recognising the health inequities for indigenous and first nations’ peoples.
“We believe that patients, communities and the biopharmaceutical industry must work together to ‘do now what patients and their whanau need next’. This is the purpose of our relationship commitment to Ngāti Whātua. By listening and walking with them, we can identify where our expertise can help with the better health outcomes they seek.”
